BioInvent seals antibody collaboration with Human Genome Sciences

Collaboration

BioInvent International AB and Human Genome Sciences (HGS), Inc have agreed a collaboration to discover, develop and commercialise therapeutic monoclonal antibodies which target antigens discovered by HGS.

BioInvent will apply its antibody discovery technology to generate and develop monoclonal antibody candidates in the field of inflammation. Both companies have the right to participate in the development and global commercialisation of each antibody candidate, and will share research, development, manufacturing and commercialisation costs as well as future revenues. Specific terms were not disclosed.

Svein Mathisen, CEO of BioInvent, said, “Access to commercially attractive targets to which we can apply our antibody discovery engine is an important part of BioInvent’s strategy. We believe this collaborative agreement is a strong and valuable way of building our pipeline of innovative drugs as BioInvent and HGS’s research strengths are both complementary and synergistic.”